) are jumping in early trading. The drugmaker reported second quarter results that handily beat Street estimates. The company also raised its full-year earnings and revenue guidance. Elil Lilly benefited from strong sales of its GLP-1 drugs Mounjaro and Zepbound.The company also boosted its full year revenue outlook on strong demand for its weight loss treatments.The breakdown here, I mean, if you had a penny for every Monro reference that they made you could retire, uh pretty much.
That is a 13% increase and take a look at adjusted EPS that is a 45% increase from the versus the actual and this is all being credited to Monro and Z bound, Z bound really on A I mean, it's, it's a rocket ship. So both drugs are no longer in the FDA shortage list, which means that we know that the supply constraints are a little bit easier for the year.
So, you know, little bits and pieces being put together to make this really just a bull case for the company.But again, when you take a look at the reaction lots to be excited about and like you said, it was pretty amazing all the times they were and it makes sense, right?It's almost like the A I kind of key word here for the Pharma industry and it's paid off.
Francis Ngannou pondered retirement after death of his son, but wants to do 'something good in his memory'
Portugal Últimas Notícias, Portugal Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Fonte: YahooFinanceCA - 🏆 47. / 63 Consulte Mais informação »